Cargando…

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma

BACKGROUND: Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial tumor regression in several clinical trials. However, genetically engineered T cells have been associated with serious side-effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis C., Simon, Bianca, Fujii, Shin-ichiro, Shimizu, Kanako, Uslu, Ugur, Schuler, Gerold, Gerer, Kerstin F., Hoyer, Stefanie, Dörrie, Jan, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561563/
https://www.ncbi.nlm.nih.gov/pubmed/28818060
http://dx.doi.org/10.1186/s12885-017-3539-3
_version_ 1783257851170390016
author Harrer, Dennis C.
Simon, Bianca
Fujii, Shin-ichiro
Shimizu, Kanako
Uslu, Ugur
Schuler, Gerold
Gerer, Kerstin F.
Hoyer, Stefanie
Dörrie, Jan
Schaft, Niels
author_facet Harrer, Dennis C.
Simon, Bianca
Fujii, Shin-ichiro
Shimizu, Kanako
Uslu, Ugur
Schuler, Gerold
Gerer, Kerstin F.
Hoyer, Stefanie
Dörrie, Jan
Schaft, Niels
author_sort Harrer, Dennis C.
collection PubMed
description BACKGROUND: Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial tumor regression in several clinical trials. However, genetically engineered T cells have been associated with serious side-effects due to off-target toxicities and massive cytokine release. To obviate these concerns, we established a protocol adaptable to GMP to expand and transiently transfect γ/δ T cells with mRNA. METHODS: PBMC from healthy donors were stimulated using zoledronic-acid or OKT3 to expand γ/δ T cells and bulk T cells, respectively. Additionally, CD8(+) T cells and γ/δ T cells were MACS-isolated from PBMC and expanded with OKT3. Next, these four populations were electroporated with RNA encoding a gp100/HLA-A2-specific TCR or a CAR specific for MCSP. Thereafter, receptor expression, antigen-specific cytokine secretion, specific cytotoxicity, and killing of the endogenous γ/δ T cell-target Daudi were analyzed. RESULTS: Using zoledronic-acid in average 6 million of γ/δ T cells with a purity of 85% were generated from one million PBMC. MACS-isolation and OKT3-mediated expansion of γ/δ T cells yielded approximately ten times less cells. OKT3-expanded and CD8(+) MACS-isolated conventional T cells behaved correspondingly similar. All employed T cells were efficiently transfected with the TCR or the CAR. Upon respective stimulation, γ/δ T cells produced IFNγ and TNF, but little IL-2 and the zoledronic-acid expanded T cells exceeded MACS-γ/δ T cells in antigen-specific cytokine secretion. While the cytokine production of γ/δ T cells was in general lower than that of conventional T cells, specific cytotoxicity against melanoma cell lines was similar. In contrast to OKT3-expanded and MACS-CD8(+) T cells, mock-electroporated γ/δ T cells also lysed tumor cells reflecting the γ/δ T cell-intrinsic anti-tumor activity. After transfection, γ/δ T cells were still able to kill MHC-deficient Daudi cells. CONCLUSION: We present a protocol adaptable to GMP for the expansion of γ/δ T cells and their subsequent RNA-transfection with tumor-specific TCRs or CARs. Given the transient receptor expression, the reduced cytokine release, and the equivalent cytotoxicity, these γ/δ T cells may represent a safer complementation to genetically engineered conventional T cells in the immunotherapy of melanoma (Exper Dermatol 26: 157, 2017, J Investig Dermatol 136: A173, 2016). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3539-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5561563
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55615632017-08-18 RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma Harrer, Dennis C. Simon, Bianca Fujii, Shin-ichiro Shimizu, Kanako Uslu, Ugur Schuler, Gerold Gerer, Kerstin F. Hoyer, Stefanie Dörrie, Jan Schaft, Niels BMC Cancer Research Article BACKGROUND: Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial tumor regression in several clinical trials. However, genetically engineered T cells have been associated with serious side-effects due to off-target toxicities and massive cytokine release. To obviate these concerns, we established a protocol adaptable to GMP to expand and transiently transfect γ/δ T cells with mRNA. METHODS: PBMC from healthy donors were stimulated using zoledronic-acid or OKT3 to expand γ/δ T cells and bulk T cells, respectively. Additionally, CD8(+) T cells and γ/δ T cells were MACS-isolated from PBMC and expanded with OKT3. Next, these four populations were electroporated with RNA encoding a gp100/HLA-A2-specific TCR or a CAR specific for MCSP. Thereafter, receptor expression, antigen-specific cytokine secretion, specific cytotoxicity, and killing of the endogenous γ/δ T cell-target Daudi were analyzed. RESULTS: Using zoledronic-acid in average 6 million of γ/δ T cells with a purity of 85% were generated from one million PBMC. MACS-isolation and OKT3-mediated expansion of γ/δ T cells yielded approximately ten times less cells. OKT3-expanded and CD8(+) MACS-isolated conventional T cells behaved correspondingly similar. All employed T cells were efficiently transfected with the TCR or the CAR. Upon respective stimulation, γ/δ T cells produced IFNγ and TNF, but little IL-2 and the zoledronic-acid expanded T cells exceeded MACS-γ/δ T cells in antigen-specific cytokine secretion. While the cytokine production of γ/δ T cells was in general lower than that of conventional T cells, specific cytotoxicity against melanoma cell lines was similar. In contrast to OKT3-expanded and MACS-CD8(+) T cells, mock-electroporated γ/δ T cells also lysed tumor cells reflecting the γ/δ T cell-intrinsic anti-tumor activity. After transfection, γ/δ T cells were still able to kill MHC-deficient Daudi cells. CONCLUSION: We present a protocol adaptable to GMP for the expansion of γ/δ T cells and their subsequent RNA-transfection with tumor-specific TCRs or CARs. Given the transient receptor expression, the reduced cytokine release, and the equivalent cytotoxicity, these γ/δ T cells may represent a safer complementation to genetically engineered conventional T cells in the immunotherapy of melanoma (Exper Dermatol 26: 157, 2017, J Investig Dermatol 136: A173, 2016). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3539-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-17 /pmc/articles/PMC5561563/ /pubmed/28818060 http://dx.doi.org/10.1186/s12885-017-3539-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Harrer, Dennis C.
Simon, Bianca
Fujii, Shin-ichiro
Shimizu, Kanako
Uslu, Ugur
Schuler, Gerold
Gerer, Kerstin F.
Hoyer, Stefanie
Dörrie, Jan
Schaft, Niels
RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title_full RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title_fullStr RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title_full_unstemmed RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title_short RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
title_sort rna-transfection of γ/δ t cells with a chimeric antigen receptor or an α/β t-cell receptor: a safer alternative to genetically engineered α/β t cells for the immunotherapy of melanoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561563/
https://www.ncbi.nlm.nih.gov/pubmed/28818060
http://dx.doi.org/10.1186/s12885-017-3539-3
work_keys_str_mv AT harrerdennisc rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT simonbianca rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT fujiishinichiro rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT shimizukanako rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT usluugur rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT schulergerold rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT gererkerstinf rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT hoyerstefanie rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT dorriejan rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma
AT schaftniels rnatransfectionofgdtcellswithachimericantigenreceptororanabtcellreceptorasaferalternativetogeneticallyengineeredabtcellsfortheimmunotherapyofmelanoma